INNOCAN PHARMA Corp
INNPF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.36 | -0.75 | 0.21 | 0.51 |
| FCF Yield | -3.72% | -5.25% | -11.68% | -4.77% |
| EV / EBITDA | -31.19 | -18.92 | -12.78 | -17.47 |
| Quality | ||||
| ROIC | 5.06% | 90.63% | -100.14% | -83.00% |
| Gross Margin | 88.96% | 87.71% | 82.34% | 61.73% |
| Cash Conversion Ratio | 6.03 | 0.83 | 1.56 | 0.66 |
| Growth | ||||
| Revenue 3-Year CAGR | 125.74% | 311.50% | 583.90% | – |
| Free Cash Flow Growth | 59.65% | 35.17% | 8.65% | -80.91% |
| Safety | ||||
| Net Debt / EBITDA | 4.12 | 1.02 | 1.33 | 1.50 |
| Interest Coverage | -178.14 | 0.00 | -3,133.00 | -575.38 |
| Efficiency | ||||
| Inventory Turnover | 0.98 | 0.97 | 0.40 | 0.15 |
| Cash Conversion Cycle | 360.25 | 360.27 | 871.25 | 2,224.07 |